Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type

Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated biomarkers of efficacy for ICIs. These markers remain imperfect, and new predictive marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalens, Lorraine, Lecuelle, Julie, Favier, Laure, Fraisse, Cléa, Lagrange, Aurélie, Kaderbhai, Courèche, Boidot, Romain, Chevrier, Sandy, Mananet, Hugo, Derangère, Valentin, Truntzer, Caroline, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144126/
https://www.ncbi.nlm.nih.gov/pubmed/37108755
http://dx.doi.org/10.3390/ijms24087592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144126/
https://www.ncbi.nlm.nih.gov/pubmed/37108755
http://dx.doi.org/10.3390/ijms24087592

Ejemplares similares